The DOI matches its Crossref record; 161 of the 164 references it cites were found in a registry or an index.
Targeting the Incretin/Glucagon System With Triagonists to Treat Diabetes
Open accessAbstract
Glucagonlike peptide 1 (GLP-1) receptor agonists have been efficacious for the treatment of type 2 diabetes due to their ability to reduce weight and attenuate hyperglycemia. However, the activity of glucagonlike peptide 1 receptor–directed strategies is submaximal, and the only potent, sustainable treatment of metabolic dysfunction is bariatric surgery, necessitating the development of unique therapeutics. GLP-1 is structurally related to glucagon and glucose-dependent insulinotropic peptide (GIP), allowing for the development of intermixed, unimolecular peptides with activity at each of their respective receptors. In this review, we discuss the range of tissue targets and added benefits afforded by the inclusion of each of GIP and glucagon. We discuss considerations for the development of sequence-intermixed dual agonists and triagonists, highlighting the importance of evaluating balanced signaling at the targeted receptors. Several multireceptor agonist peptides have been developed and evaluated, and the key preclinical and clinical findings are reviewed in detail. The biological activity of these multireceptor agonists are founded in the success of GLP-1-directed strategies; by including GIP and glucagon components, these multireceptor agonists are thought to enhance GLP-1’s activities by broadening the tissue targets and synergizing at tissues that express multiple receptors, such at the brain and pancreatic isletβ cells. The development and utility of balanced, unimolecular multireceptor agonists provide both a useful tool for querying the actions of incretins and glucagon during metabolic disease and a unique drug class to treat type 2 diabetes with unprecedented efficacy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“However, this multi-receptor agonism approach to weight loss was hindered by commercial considerations of production and formulation [45], the biological impasse that glucagon potently induces hyperglycemia [56,57], and potential dose-limiting cardiovascular liabilities arising from positive chronotropic actions to influence hemodynamic parameters [58].”
From Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice (2022) · cites this paper as [45]
The cited source says what the claim attributes to it.
In the citing paper
“These compounds, termed triagonists or triple agonists, couple the weight-reducing efficacy of GLP-1R, GIPR, and GcgR agonism while simultaneously buffering the glycemic effects of Gcg with dual incretin receptor activation [43,45].”
From Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice (2022) · cites this paper as [45]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“In particular, it inhibits hepatic synthesis and promotes beta-oxidation of fatty acids [148,150] and, probably, lipolysis in adipose tissue [151].”
From GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives (2023) · cites this paper as [148]
Experimental — accuracy not yet measuredIn the citing paper
“However, glucagon counteracts the insulin action, promoting gluconeogenesis and hepatic glycogenolysis [148].”
From GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives (2023) · cites this paper as [148]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Genetics of Food Intake Self-Regulation in Childhood: Literature Review and Research Opportunities
Faith, M. S., Carnell, S., & Kral, T. V. E. (2013) · Human Heredity · doi:10.1159/000353879 · Cited by 7,601
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Biology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639
Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index
MAGIC, Speliotes, E. K., on behalf of Procardis Consortium, Willer, C. J., Berndt, S. I., Monda, K. L., Thorleifsson, G., Jackson, A. U., Allen, H. L., Lindgren, C. M., et al. (2010) · Nature Genetics · doi:10.1038/ng.686 · Cited by 2,912
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
Pfeffer, M. A., Claggett, B., Diaz, R., Dickstein, K., Gerstein, H. C., Køber, L. V., Lawson, F. C., Ping, L., Wei, X., Lewis, E. F., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1509225 · Cited by 2,409
Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes
Holman, R. R., Bethel, M. A., Mentz, R. J., Thompson, V. P., Lokhnygina, Y., Buse, J. B., Chan, J. C., Choi, J., Gustavson, S. M., Iqbal, N., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612917 · Cited by 2,162
Glucagon-like peptide-1 7–36: a physiological incretin in man
Kreymann, B., Ghatei, M. A., Williams, G., & Bloom, S. R. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91194-9 · Cited by 1,928
Nauck, M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., & Creutzfeldt, W. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116186 · Cited by 1,651
Brain insulin resistance in type 2 diabetes and Alzheimer disease: concepts and conundrums
Arnold, S. E., Arvanitakis, Z., Macauley-Rambach, S. L., Koenig, A. M., Wang, H.-Y., Ahima, R. S., Craft, S., Gandy, S., Buettner, C., Stoeckel, L. E., et al. (2018) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.185 · Cited by 1,597
Cited by
Blüher, M. (2020) · Endocrine Reviews · doi:10.1210/endrev/bnaa004 · Cited by 1,090
“Moreover, based on the metabolic benefits demonstrated for GLP-1/glucagon and GLP-1/GIP coagonists (“twincretins”), triagonists targeting all 3 incretin receptors have been systematically developed with even stronger efficacy compared to twincretins on weight loss and obesity-related traits, such as reducing liver fat…”
BackgroundFunction and mechanisms of enteroendocrine cells and gut hormones in metabolism
Gribble, F. M., & Reimann, F. (2019) · Nature Reviews Endocrinology · doi:10.1038/s41574-019-0168-8 · Cited by 670
Mechanisms controlling pancreatic islet cell function in insulin secretion
Campbell, J. E., & Newgard, C. B. (2021) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-020-00317-7 · Cited by 629
Self-citationCoskun, T., Urva, S., Roell, W. C., Qu, H., Loghin, C., Moyers, J. S., O’Farrell, L. S., Briere, D. A., Sloop, K. W., Thomas, M. K., et al. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.07.013 · Cited by 316
Kopp, K. O., Glotfelty, E. J., Li, Y., & Greig, N. H. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106550 · Cited by 298
Nevola, R., Epifani, R., Imbriani, S., Tortorella, G., Aprea, C., Galiero, R., Rinaldi, L., Marfella, R., & Sasso, F. C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021703 · Cited by 286
“In particular, it inhibits hepatic synthesis and promotes beta-oxidation of fatty acids [148,150] and, probably, lipolysis in adipose tissue [151].”
BackgroundPharmacotherapy of obesity: available medications and drugs under investigation.
Pilitsi, E., Farr, O. M., Polyzos, S. A., Perakakis, N., Nolen-Doerr, E., Papathanasiou, A.-E., & Mantzoros, C. S. (2019) · Metabolism · doi:10.1016/j.metabol.2018.10.010 · Cited by 248
Pharmacological treatment of hyperglycemia in type 2 diabetes
Taylor, S. I., Yazdi, Z. S., & Beitelshees, A. L. (2021) · Journal of Clinical Investigation · doi:10.1172/jci142243 · Cited by 245
Glucagon Receptor Signaling and Lipid Metabolism
Galsgaard, K. D., Pedersen, J., Knop, F. K., Holst, J. J., & Wewer Albrechtsen, N. J. (2019) · Frontiers in Physiology · doi:10.3389/fphys.2019.00413 · Cited by 218
Xu, Y., Shrestha, N., Préat, V., & Beloqui, A. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.04.006 · Cited by 214
Glucagon Receptor Signaling and Glucagon Resistance
Janah, L., Kjeldsen, S., Galsgaard, K. D., Winther-Sørensen, M., Stojanovska, E., Pedersen, J., Knop, F. K., Holst, J. J., & Wewer Albrechtsen, N. J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20133314 · Cited by 203
“As a result, a number of clinical studies are evaluating the potential for glucagon/GLP-1 receptor co-agonists for obesity and type 2 diabetes treatment [9].”
BackgroundGlucagon lowers glycemia when β cells are active
Capozzi, M. E., Wait, J. B., Koech, J., Gordon, A. N., Coch, R. W., Svendsen, B., Finan, B., D’Alessio, D. A., & Campbell, J. E. (2019) · JCI Insight · doi:10.1172/jci.insight.129954 · Cited by 165
Self-citationNew Frontiers in Obesity Treatment: GLP-1 and Nascent Nutrient-Stimulated Hormone-Based Therapeutics
Jastreboff, A. M., & Kushner, R. F. (2023) · Annual Review of Medicine · doi:10.1146/annurev-med-043021-014919 · Cited by 158
The Liver–α-Cell Axis and Type 2 Diabetes
Albrechtsen, N. J. W., Pedersen, J., Galsgaard, K. D., Winther‐Sørensen, M., Suppli, M. P., Janah, L., Gromada, J., Vilstrup, H., Knop, F. K., & Holst, J. J. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00251 · Cited by 162
Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice
Knerr, P. J., Mowery, S. A., Douros, J. D., Premdjee, B., Hjøllund, K. R., He, Y., Kruse Hansen, A. M., Olsen, A. K., Perez-Tilve, D., DiMarchi, R. D., et al. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2022.101533 · Cited by 152
“These compounds, termed triagonists or triple agonists, couple the weight-reducing efficacy of GLP-1R, GIPR, and GcgR agonism while simultaneously buffering the glycemic effects of Gcg with dual incretin receptor activation [43,45].”
BackgroundSelf-citationTargeting the GIPR for obesity: To agonize or antagonize? Potential mechanisms
Campbell, J. E. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101139 · Cited by 133
“Nonetheless, the consistent observation that combining GIPR and GLP-1R agonism greatly reduces weight loss has spurred the investigation of single peptide agonists that have dual activity at both receptors for treating obesity and diabetes [7].”
BackgroundSelf-citationKabahizi, A., Wallace, B., Lieu, L., Chau, D., Dong, Y., Hwang, E., & Williams, K. W. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15682 · Cited by 126
“Tri-agonists in preclinical/clinical research have also demonstrated some superior beneficial effects compared to dual agonists, which include reduction of body weight, enhancement of glycaemic control and the reversal of nonalcoholic steatohepatitis (NASH) (Capozzi et al., 2018).”
BackgroundInfluentialCabri, W., Cantelmi, P., Corbisiero, D., Fantoni, T., Ferrazzano, L., Martelli, G., Mattellone, A., & Tolomelli, A. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.697586 · Cited by 134
Tirzepatide: A Systematic Update
Forzano, I., Varzideh, F., Avvisato, R., Jankauskas, S. S., Mone, P., & Santulli, G. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232314631 · Cited by 118
Repositioning Glucagon Action in the Physiology and Pharmacology of Diabetes
Finan, B., Capozzi, M. E., & Campbell, J. E. (2019) · Diabetes · doi:10.2337/dbi19-0004 · Cited by 132
“This model incorporates new consideration of the secretion of glucagon, its insulinotropic actions, and activation of the GLP-1R and effectiveness in combination with GLP-1 as a therapy for T2D (69).”
BackgroundMethodSelf-citationPirro, V., Roth, K. D. W., Lin, Y., Willency, J. A., Milligan, P. L., Wilson, J. M., Ruotolo, G., Haupt, A., Newgard, C. B., & Duffin, K. L. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab722 · Cited by 125
The past, present, and future physiology and pharmacology of glucagon
Capozzi, M. E., D’Alessio, D. A., & Campbell, J. E. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.10.001 · Cited by 117
Self-citationThe role of GIP in α-cells and glucagon secretion
EL, K. M., & Campbell, J. E. (2019) · Peptides · doi:10.1016/j.peptides.2019.170213 · Cited by 114
“The potential metabolic actions of glucagon beyond the regulation of endogenous glucose production has sparked the development of agents that enhance glucagon receptor activity, often in combination with GLP-1R agonism [18].”
BackgroundSelf-citationThe Role of α-Cells in Islet Function and Glucose Homeostasis in Health and Type 2 Diabetes
Gilon, P. (2020) · Journal of Molecular Biology · doi:10.1016/j.jmb.2020.01.004 · Cited by 98
Beaudry, J. L., Kaur, K. D., Varin, E. M., Baggio, L. L., Cao, X., Mulvihill, E. E., Stern, J. H., Campbell, J. E., Scherer, P. E., & Drucker, D. J. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.01.011 · Cited by 93
“The clinical development of investigational GCG-containing multi-agonists, including oxyntomodulin and its derivatives [3,24,25], for the treatment of diabetes and obesity has rekindled interest in whether and how GCGR signaling results in BAT activation and increased energy expenditure [2,26,27].”
BackgroundSelf-citationLabeling and Characterization of Human GLP-1-Secreting L-cells in Primary Ileal Organoid Culture
Goldspink, D. A., Lu, V. B., Miedzybrodzka, E. L., Smith, C. A., Foreman, R. E., Billing, L., Kay, R. G., Reimann, F. M., & Gribble, F. M. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107833 · Cited by 101
Gilroy, C. A., Capozzi, M. E., Varanko, A. K., Tong, J., D’Alessio, D. A., Campbell, J. E., & Chilkoti, A. (2020) · Science Advances · doi:10.1126/sciadv.aaz9890 · Cited by 85
“These coagonist molecules appear to amplify the effects of GLP-1 while broadening its therapeutic window (38) and are now moving into clinical trials (37, 39).”
BackgroundSelf-citationThe incretin/glucagon system as a target for pharmacotherapy of obesity
Del Prato, S., Gallwitz, B., Holst, J. J., & Meier, J. J. (2022) · Obesity Reviews · doi:10.1111/obr.13372 · Cited by 77
“GIPR agonism alone has been shown to reduce bodyweight in mice with obesity, as observed with GIPR agonists with a longer half-life than endogenous GIP.”
BackgroundInfluentialFrías, J. P. (2020) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2020.1830759 · Cited by 82
Recent Updates on Obesity Treatments: Available Drugs and Future Directions
Dragano, N. R. V., Fernø, J., Diéguez, C., López, M., & Milbank, E. (2020) · Neuroscience · doi:10.1016/j.neuroscience.2020.04.034 · Cited by 84
Costes, S., Bertrand, G., & Ravier, M. A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22105303 · Cited by 81
Central Nervous System Control of Glucose Homeostasis: A Therapeutic Target for Type 2 Diabetes?
Mirzadeh, Z., Faber, C. L., & Schwartz, M. W. (2022) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-052220-010446 · Cited by 76
The Involvement of Peripheral and Brain Insulin Resistance in Late Onset Alzheimer’s Dementia
Folch, J., Olloquequi, J., Ettcheto, M., Busquets, O., Sánchez‐López, E., Cano, A. C., Espinosa-Jiménez, T., García, M. L., Beas‐Zárate, C., Casadesús, G., et al. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00236 · Cited by 94
Pharmacological antagonism of the incretin system protects against diet-induced obesity
Svendsen, B., Capozzi, M. E., Nui, J., Hannou, S. A., Finan, B., Naylor, J., Ravn, P., D'Alessio, D. A., & Campbell, J. E. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2019.11.018 · Cited by 67
“Numerous co-agonists that incorporate GIPR activity have demonstrated robust effects on decreasing body weight [2], highlighted most recently by phase 2 clinical results of tirzepatide [34].”
BackgroundSelf-citationPeptide‐based multi‐agonists: a new paradigm in metabolic pharmacology
Brandt, S. J., Müller, T. D., DiMarchi, R. D., Tschöp, M., & Stemmer, K. (2018) · Journal of Internal Medicine · doi:10.1111/joim.12837 · Cited by 71
Self-citationGlucagon-like peptide-1 (GLP-1)-based receptor agonists as a treatment for Parkinson’s disease
Glotfelty, E. J., Olson, L., Karlsson, T. E., Li, Y., & Greig, N. H. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1764534 · Cited by 70
“It is important to consider that genetically modified mice that knock out certain receptors may compensate for these absences and exhibit atypical physiological responses to the monomeric multi-agonists [35].”
BackgroundHepatic glucagon action: beyond glucose mobilization
Kajani, S., Laker, R. C., Ratkova, E. L., Will, S., & Rhodes, C. J. (2024) · Physiological Reviews · doi:10.1152/physrev.00028.2023 · Cited by 71
The Natural Metabolite 4-Cresol Improves Glucose Homeostasis and Enhances β-Cell Function
Brial, F., Alzaïd, F., Sonomura, K., Meneyrol, K., Lay, A. L., Pean, N., Neves, A. L., Chilloux, J., Hedjazi, L., Sato, T.-A., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.01.066 · Cited by 64
“4-Cresol Stimulates b-Cell Proliferation in Mouse Isolated Islets We next assessed the effect of 4-cresol on b-cell proliferation in vitro, which we compared to that of the incretin hormone glucagon-like peptide-1 (GLP-1), a well-established therapeutic target in diabetes (Capozzi et al., 2018; Tudurı́ et al., 2016) t…”
ResultRole of Glucagon and Its Receptor in the Pathogenesis of Diabetes
Jia, Y., Liu, Y., Feng, L., Sun, S., & Sun, G. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.928016 · Cited by 68
Verhaegen, A. A., & Van Gaal, L. F. (2021) · Current Obesity Reports · doi:10.1007/s13679-020-00419-5 · Cited by 53
Pharmacotherapy of obesity: An update
Cignarella, A., Busetto, L., & Vettor, R. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105649 · Cited by 65
Eid, L. E., Reynolds, C. A., Tomás, A., & Jones, B. J. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106411 · Cited by 57
Knerr, P. J., Mowery, S. A., Finan, B., Perez-Tilve, D., Tschöp, M. H., & DiMarchi, R. D. (2020) · Peptides · doi:10.1016/j.peptides.2019.170225 · Cited by 49
Self-citationGlucagon, GLP-1 and Thermogenesis
González-García, I., Milbank, E., Diéguez, C., López, M., & Contreras, C. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20143445 · Cited by 49
“The most relevant results were obtained jointly by the Di Marchi and Tschöp groups [33,34], showing promising results in the management of metabolic pathologies such as obesity and diabetes.”
Incretin Mimetics as Rational Candidates for the Treatment of Traumatic Brain Injury
Glotfelty, E. J., Delgado, T., Tovar‐y‐Romo, L. B., Luo, Y., Hoffer, B. J., Olson, L., Karlsson, T. E., Mattson, M. P., Harvey, B. K., Tweedie, D., et al. (2019) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.9b00003 · Cited by 50
Zafer, M., Tavaglione, F., Romero‐Gómez, M., & Loomba, R. (2025) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70196 · Cited by 47
Blanchi, B., Taurand, M., Sauty-Colace, C., Thomaidou, S., Audeoud, C., Fantuzzi, F., Sawatani, T., Gheibi, S., Sabadell‐Basallote, J., Boot, F., et al. (2023) · Molecular Metabolism · doi:10.1016/j.molmet.2023.101772 · Cited by 59
“This identi fi es EndoC-b H5 cells as a unique human cellular model to study recently developed dual and triple GLP-1/GIP/GCG receptor agonists [48,49].”
Friedrichsen, M. H., Endahl, L., Kreiner, F. F., Goldwater, R., Kankam, M., Toubro, S., & Nygård, S. B. (2023) · Molecular Metabolism · doi:10.1016/j.molmet.2023.101801 · Cited by 46
“The key to unlocking the optimal combination of agonism may lie in understanding the implications of relative pharmacological activity at each receptor, and the optimal balance may depend on the indication, i.e. weight loss or glycaemic control [59].”
BackgroundGlucagon in type 2 diabetes: Friend or foe?
Caruso, I., Marrano, N., Biondi, G., Genchi, V. A., D'Oria, R., Sorice, G. P., Perrini, S., Cignarelli, A., Natalicchio, A., Laviola, L., et al. (2023) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3609 · Cited by 35
“Nowadays, both dual and triple agonists incorporating glucagon agonism are under development for clinical use.(75,131,137) Experimental studies conducted in diet‐induced obese mice showed that dual GLP‐1/GCGR agonists induced weight loss, improved lipid and glycaemic profile, increased EE, and reduced food intake.”
BackgroundResultInfluentialChepurny, O. G., Matsoukas, M., Liapakis, G., Leech, C. A., Milliken, B. T., Doyle, R. P., & Holz, G. G. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.005682 · Cited by 41
Cryo-electron microscopy structure of the glucagon receptor with a dual-agonist peptide
Chang, R., Zhang, X., Qiao, A., Dai, A., Belousoff, M. J., Tan, Q., Shao, L., Li, Z., Lin, G., Liang, Y.-L., et al. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra120.013793 · Cited by 42
“The peptide had approximately equal potency to GLP-1(7-36)NH2 in CHO-K1 cells expressing the WT human GLP-1R (Fig.”
BackgroundInsights into incretin-based therapies for treatment of diabetic dyslipidemia
Stemmer, K., Finan, B., DiMarchi, R. D., Tschöp, M. H., & Müller, T. D. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.05.008 · Cited by 43
“Similar peptide analogs of GLP-1, GIP and glucagon facilitated the design of an intermixed single-sequence peptide for the parallel targeting of the two incretin and glucagon receptors [176,262].”
BackgroundSelf-citationDiscordance between GLP-1R gene and protein expression in mouse pancreatic islet cells
Gray, S. M., Xin, Y., Ross, E. C., Chazotte, B. M., Capozzi, M. E., EL, K. M., Svendsen, B., Ravn, P., Sloop, K. W., Tong, J., et al. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra120.014368 · Cited by 47
“The abbreviations used are: T2D, type 2 diabetes; APC, allophycocyanin; NP, nulliparous; MP, multiparous; ANOVA, analysis of variance; qPCR, quantitative PCR.”
BackgroundInfluentialSelf-citationGlucagon-based therapy: Past, present and future
Patil, M., Deshmukh, N., Patel, M. V., & Sangle, G. V. (2020) · Peptides · doi:10.1016/j.peptides.2020.170296 · Cited by 37
An ‘Ayurveda-Biology’ platform for integrative diabetes management
Thottappillil, A., Kouser, S., Kukkupuni, S. K., & Vishnuprasad, C. N. (2020) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2020.113575 · Cited by 46
The Design of a GLP‐1/PYY Dual Acting Agonist
Østergaard, S., Paulsson, J. F., Gerstenberg, M. K., & Wulff, B. S. (2021) · Angewandte Chemie International Edition · doi:10.1002/anie.202016464 · Cited by 38
Nutrient Regulation of Pancreatic Islet β-Cell Secretory Capacity and Insulin Production
Rohli, K. E., Boyer, C. K., Blom, S. E., & Stephens, S. B. (2022) · Biomolecules · doi:10.3390/biom12020335 · Cited by 41
Regulation of thermogenic adipocytes during fasting and cold
Reinisch, I., Schreiber, R., & Prokesch, A. (2020) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2020.110869 · Cited by 36
Evaluation of biased agonism mediated by dual agonists of the GLP-1 and glucagon receptors
Darbalaei, S., Yuliantie, E., Dai, A., Chang, R., Zhao, P., Yang, D., Wang, M.-W., Sexton, P. M., & Wootten, D. L. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114150 · Cited by 37
Mechanisms of action of incretin receptor based dual- and tri-agonists in pancreatic islets
Folli, F. B., Finzi, G., Manfrini, R., Galli, A., Casiraghi, F., Centofanti, L., Berra, C., Fiorina, P., Davalli, A. M., Rosa, S. L., et al. (2023) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00236.2023 · Cited by 35
Nishizaki, H., Matsuoka, O., Kagawa, T., Kobayashi, A., Watanabe, M., & Moritoh, Y. (2021) · Diabetes · doi:10.2337/db21-0451 · Cited by 36
“Therefore, coagonists combining glucagon receptor activity with GLP-1R agonism are being developed as antidiabetes and antiobesity medications and have shown promising effects on glycemic control and body weight loss (27).”
BackgroundGlucagon Resistance and Decreased Susceptibility to Diabetes in a Model of Chronic Hyperglucagonemia
Bozadjieva-Kramer, N., Lubaczeuski, C., Blandino-Rosano, M., Barker, G. P., Gittes, G. K., Caicedo, A., & Bernal‐Mizrachi, E. (2020) · Diabetes · doi:10.2337/db20-0440 · Cited by 32
“Interestingly, pharmaceutical companies have developed GLP1R and CGCR coagonists as therapy for diabetes and obesity (9,42).”
Li, Y., Glotfelty, E. J., Namdar, I., Tweedie, D., Olson, L., Hoffer, B. J., DiMarchi, R. D., Pick, C. G., & Greig, N. H. (2019) · Experimental Neurology · doi:10.1016/j.expneurol.2019.113113 · Cited by 31
Self-citationCrosstalk Communications Between Islets Cells and Insulin Target Tissue: The Hidden Face of Iceberg
Langlois, A., Dumond, A., Vion, J., Pinget, M., & Bouzakri, K. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.836344 · Cited by 35
“The same observation was done if the receptors for proglucagon peptides (GLP-1R and GCGR) are silenced (37, 40, 41).”
BackgroundMetabolic Benefits of MicroRNA-22 Inhibition
Thibonnier, M., & Esau, C. (2019) · Nucleic Acid Therapeutics · doi:10.1089/nat.2019.0820 · Cited by 29
“Interestingly enough, double and triple combinations of in-cretins (guthormones) arecurrently developedfor the treatment of type 2 diabetes mellitus and/or obesity [81–86].”
Deng, F., Wu, W., Fan, X., Zhong, X., Wang, N., Wang, Y., Pan, T., & Du, Y. (2023) · International Journal of Endocrinology · doi:10.1155/2023/9926462 · Cited by 26
Chen, Y., Xu, R., Ruze, R., Yang, J., Wang, H., Song, J., You, L., Wang, C., & Zhao, Y. (2021) · Cancer Cell International · doi:10.1186/s12935-021-01928-6 · Cited by 28
Emerging and Established Therapeutic Approaches for Nonalcoholic Fatty Liver Disease
Brown, E. E., Hydes, T., Hamid, A., & Cuthbertson, D. J. (2021) · Clinical Therapeutics · doi:10.1016/j.clinthera.2021.07.013 · Cited by 31
Mechanisms of Cardiorenal Protection of Glucagon-Like Peptide-1 Receptor Agonists
Tommerdahl, K. L., Nadeau, K. J., & Bjornstad, P. (2021) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2021.06.001 · Cited by 29
Muzurović, E. M., Katsiki, N., Volčanšek, Š., Plescia, F., Rizzo, M., & Mantzoros, C. S. (2026) · Metabolism · doi:10.1016/j.metabol.2026.156494 · Cited by 25
Niotis, K., Saperia, C., Saif, N., Carlton, C., & Isaacson, R. (2024) · Nature Mental Health · doi:10.1038/s44220-023-00191-0 · Cited by 21
“Glucagon-like peptide-1 (GLP-1) is a hormone that promotes insulin signaling, blood sugar regulation and appetite suppression 59,60 , and GLP-1 agonists have become useful in the treatment of T2DM.”
Cardiovascular biology of the GIP receptor
Greenwell, A. A., Chahade, J. J., & Ussher, J. R. (2019) · Peptides · doi:10.1016/j.peptides.2019.170228 · Cited by 23
Finan, B., Douros, J. D., Goldwater, R., Hansen, A. M. K., Hjerpsted, J., Hjøllund, K. R., Kankam, M. K., Knerr, P. J., Konkar, A. A., Mowery, S. A., et al. (2025) · Molecular Metabolism · doi:10.1016/j.molmet.2025.102129 · Cited by 21
“Therefore, most GLP-1R/GcgR co-agonists have purposefully and substantially reduced GcgR potency relative to GLP-1R potency [45], which can explain the relatively modest differential clinical ef fi cacy to GLP-1R mono-agonists.”
Self-citationRISING STARS: Endocrine regulation of metabolic homeostasis via the intestine and gut microbiome
Meyer, R. K., & Duca, F. A. (2023) · Journal of Endocrinology · doi:10.1530/joe-23-0019 · Cited by 28
Beaudry, J. L., & Drucker, D. J. (2019) · Endocrinology · doi:10.1210/endocr/bqz029 · Cited by 24
“multi-agonists containing two or three peptide epitopes, including glucagon GLP-1 and GIP, are under investigation for the therapy of metabolic disorders (6, 7).”
BackgroundLiu, J., Liu, S., Gurung, R. L., Chan, C., Ang, K., Tang, W. E., Subramaniam, T., Sum, C. F., & Lim, S. C. (2018) · Journal of the Endocrine Society · doi:10.1210/js.2018-00321 · Cited by 19
“A greater glucagon level might prompt the body to access stored nutrients, increase hepatic glucose production from glycogen and amino acids, and promote lipolysis [32, 34].”
BackgroundBatran, R. A., Gopal, K., Aburasayn, H., Eshreif, A., Almutairi, M. G., Greenwell, A. A., Campbell, S. A., Saleme, B., Court, E. A., Eaton, F., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.124643 · Cited by 19
“Because of these positive actions of glucagon on energy expenditure, a number of studies have explored whether glucagon receptor agonism, or combining activation of both glucagon and glucagon-like peptide-1 receptors with new peptide coagonists, can be used as a novel approach to mitigate obesity (21).”
BackgroundReprint of: Recent Updates on Obesity Treatments: Available Drugs and Future Directions
Dragano, N. R. V., Fernø, J., Diéguez, C., López, M., & Milbank, E. (2020) · Neuroscience · doi:10.1016/j.neuroscience.2020.08.009 · Cited by 21
GLP-1R agonists and heart failure: novel beneficial effects suggested by Mendelian randomization
Hu, Y., Zhao, Y., Dai, N., Zhou, Y., Yao, Y., Li, Z., Cai, W., Xiong, W., Song, S., Deng, X., et al. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf1066 · Cited by 24
Broad-spectrum ginsentides are principal bioactives in unraveling the cure-all effects of ginseng
Loo, S., Kam, A., Dutta, B., Zhang, X., Feng, N., Sze, S. K., Liu, C., Wang, X., & Tam, J. P. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.10.022 · Cited by 18
“Successful examples include GLP-like peptides for type 2 diabetes and obesity, Guaylin for irritable bowel syndrome, and conotoxins for pain management 69 e 71 .”
BackgroundGirges, C., Vijiaratnam, N., Athauda, D. S., Auld, G., Gandhi, S., & Foltynie, T. (2021) · Drugs & Aging · doi:10.1007/s40266-021-00853-7 · Cited by 18
Kobayashi, M., Maruyama, N., Yamamoto, Y., Togawa, T., Ida, T., Yoshida, M., Miyazato, M., Kitada, M., Hayashi, Y., Kashiwagi, A., et al. (2023) · Journal of Diabetes Investigation · doi:10.1111/jdi.13986 · Cited by 17
“Glucagon Glucagon (19-29) (1-16) HRP conjugated -”
Incretin triple agonist retatrutide (LY3437943) alleviates obesity-associated cancer progression
Marathe, S. J., Grey, E. W., Bohm, M. S., Joseph, S. C., Ramesh, A. V., Cottam, M. A., Idrees, K., Wellen, K. E., Hasty, A. H., Rathmell, J. C., et al. (2025) · npj Metabolic Health and Disease · doi:10.1038/s44324-025-00054-5 · Cited by 19
Poly-Agonist Pharmacotherapies for Metabolic Diseases: Hopes and New Challenges
Allard, C., Cota, D., & Quarta, C. (2023) · Drugs · doi:10.1007/s40265-023-01982-6 · Cited by 17
“The ideal balance may also depend on the specific indication, be it weight loss or glycaemic control [148].”
GIPR Agonism Enhances TZD-Induced Insulin Sensitivity in Obese IR Mice
Furber, E. C., Hyatt, K., Collins, K. A. L., Yu, X., Droz, B. A., Holland, A. K., Friedrich, J. L., Wojnicki, S., Konkol, D. L., O’Farrell, L. S., et al. (2023) · Diabetes · doi:10.2337/db23-0172 · Cited by 17
Muzurović, E. M., Dragnić, S., Medenica, S., Smolović, B., Bulajić, P., & Mikhailidis, D. P. (2020) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2020.107619 · Cited by 17
Naseralallah, L. M. A., & Aboujabal, B. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2181074 · Cited by 16
“These therapies are primarily centered on gut hormonal peptides, including the incretin-based polygonists [5].”
BackgroundLigand-Receptor Interactions and Machine Learning in GCGR and GLP-1R Drug Discovery
Mizera, M., & Latek, D. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22084060 · Cited by 15
“Known-to-date peptide compounds demonstrating a dual-action effect on glucagon receptor family members include dual agonists of GLP-1R/GIPR [23] and GLP1R/GCGR [24], and triple agonists of GLP-1R/GIPR/GCGR [2].”
BackgroundResultInfluentialTill, A., Fries, C., & Fenske, W. K. (2022) · Brain Sciences · doi:10.3390/brainsci12121646 · Cited by 14
Central and peripheral neural circuits regulating glucose homeostasis
Espinoza, D., Seibold, F., & Stanley, S. A. (2025) · npj Biomedical Innovations. · doi:10.1038/s44385-025-00036-8 · Cited by 17
“Earlytrialssuggestthattheseregimensoutperformsingleagonists schemesinbothweightlosstermsaswellaslongtermglycemic improvement 170,171 .”
Marzoog, B. A., & Vlasova, T. I. (2022) · Obesity and metabolism · doi:10.14341/omet12778 · Cited by 14
Galsgaard, K. D., Pedersen, J., Kjeldsen, S. A. S., Winther‐Sørensen, M., Stojanovska, E., Vilstrup, H., Ørskov, C., Albrechtsen, N. J. W., & Holst, J. J. (2020) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00294.2019 · Cited by 11
Current Status of Therapeutic Peptides for the Management of Diabetes Mellitus
Prajapati, A., Rana, D., Rangra, S., Jindal, A. B., & Benival, D. M. (2024) · International Journal of Peptide Research and Therapeutics · doi:10.1007/s10989-024-10590-1 · Cited by 10
“Like endogenous glucagon, balanced triagonists have around the same length and sequence as exendin-4 and GLP-1 (Capozzi et al. 2018).”
Resistencia a Insulina: Revisión de literatura
Lozano, E. S. (2022) · Revista Médica Hondureña · doi:10.5377/rmh.v90i1.13824 · Cited by 18
Darbalaei, S., Chang, R., Zhou, Q., Chen, Y., Dai, A., Wang, M., & Yang, D. (2022) · Acta Pharmacologica Sinica · doi:10.1038/s41401-022-00962-y · Cited by 9
“The concept of a dual agonist at GLP-1R and GIPR could be realized by modulating the glucagonotropic effect of GIP through balanced activation of each receptor [22, 30].”
BackgroundGuo, H., Sui, C., Ge, S., Cai, J. Q., Lin, D., Guo, Y., Wang, N., Zhou, Y., Ying, R., Zha, K., et al. (2022) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3550 · Cited by 8
A new era in gut hormone-based pharmacotherapy for people with obesity
Firman, C., & Batterham, R. L. (2022) · Proceedings of The Nutrition Society · doi:10.1017/s0029665122002695 · Cited by 10
“The therapeutic aim of this approach is that the presence of both GLP-1 and GIP, which induce satiety, increases energy expenditure and reduces energy intake, will counteract the hyperglycaemic effects of glucagon agonism by elevating insulin secretion (92, 93) .”
BackgroundKabadi, U. M. (2021) · Open Journal of Endocrine and Metabolic Diseases · doi:10.4236/ojemd.2021.113007 · Cited by 10
GPCR targets in type 2 diabetes
Atanes, P., & Persaud, S. J. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816228-6.00018-0 · Cited by 11
Designer GLP1 poly-agonist peptides in the management of diabesity
Statham, L., Pelling, M., Hanson, P., Kyrou, I., Randeva, H. S., & Barber, T. M. (2023) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2023.2204976 · Cited by 8
“Although beyond the scope of this review, the early pioneering, animal-based studies on the metabolic effects of GLP1 combined with other incretin and intestinal hormones has been reviewed elsewhere [20,21].”
Background
Metadata
- Authors
- Capozzi, M. E., DiMarchi, R. D., Tschöp, M. H., Finan, B., & Campbell, J. E.
- Affiliations
- Duke University (US)
- Indiana University Bloomington (US)
- Helmholtz Munich (DE)
- Novo Nordisk Research Center, Indianapolis, Indiana
- Corresponding author
- Campbell, Jonathan E
- Venue
- Endocrine Reviews
- Publisher
- The Endocrine Society
- Published
- 2018-06-13
- Volume
- 39
- Issue
- 5
- Pages
- 719-738
- ISSN
- 0163-769X (ISSN-L)
- 1945-7189
- PMC
- PMC7263842
- OpenAlex
- W2808030638
- Cited by
- 153
- References
- 164
- Citations by year
- 2026: 10 · 2025: 12 · 2024: 10 · 2023: 19 · 2022: 19 · 2021: 30 · 2020: 24 · 2019: 25 · 2018: 4
- FWCI
- 3.19
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Endocrine Reviews (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- mediaTUM (Technical University of Munich) (submittedVersion)
- PuSH - Publication Server of Helmholtz Zentrum München (submittedVersion)
- Funders
- NIH
- American Diabetes Association (1-18-JDF-017)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- type 2 diabetes, GLP-1 receptor agonists, glucagon, glucose-dependent insulinotropic polypeptide, incretin system, dual receptor agonist, pancreatic beta cells, brain, drug development, hyperglycemia
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptide-1 Receptor Agonists, Diabetes Mellitus, Type 2, Gastric Inhibitory Polypeptide, Humans, Hypoglycemic Agents, Glucagon-Like Peptide 1, Incretins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.